Associations of practice differences with outcomes
| Outcome . | NCCH-BMT RIC (vs MAC) . | FHCRC/SCCA-PBSCT CNI + MMF (vs CNI + MTX) . | FHCRC/SCCA-PBSCT Unrelated (vs Related) . | |||
|---|---|---|---|---|---|---|
| HR/OR (95% CI) . | P . | HR/OR (95% CI) . | P . | HR/OR (95% CI) . | P . | |
| Cumulative incidence of NIH chronic GVHD | 0.99 (0.52-1.87) | .97 | 0.90 (0.71-1.14) | 0.38 | 0.83 (0.66-1.05) | .12 |
| Liver involvement with late acute GVHD per the NIH liver score | 1.81 (0.42-7.83) | .43 | 0.35 (0.14-0.88) | 0.026 | 0.79 (0.32-1.93) | .61 |
| Gut involvement with late acute GVHD | 1.76 (0.32-9.73) | .51 | 2.55 (1.00-6.48) | 0.05 | 1.40 (0.57-3.42) | .47 |
| Mouth involvement with NIH chronic GVHD | 0.13 (0.02-0.74) | .022 | 1.09 (0.66-1.81) | 0.73 | 1.19 (0.72-1.96) | .50 |
| Eye involvement with NIH chronic GVHD | 0.71 (0.20-2.58) | .61 | 0.87 (0.54-1.42) | 0.59 | 1.16 (0.71-1.89) | .55 |
| Gut involvement with NIH chronic GVHD | 1.79 (0.10-30.8) | .69 | 1.56 (0.96-2.51) | 0.072 | 1.37 (0.85-2.21) | .19 |
| Liver involvement with NIH chronic GVHD | 0.10 (0.02-0.56) | .009 | 0.61 (0.38-1.00) | 0.044 | 0.71 (0.44-1.13) | .15 |
| Discontinued systemic treatment after late acute GVHD | 1.67 (0.72-3.89) | .23 | 0.88 (0.30-2.57) | 0.81 | 0.94 (0.32-2.78) | .91 |
| NRM after late acute GVHD | NA* | NA* | 2.24 (0.84-6.00) | 0.11 | 1.41 (0.51-3.94) | .51 |
| Progression from late acute GVHD to NIH chronic GVHD | 0.26 (0.03-2.18) | .21 | 0.69 (0.40-1.21) | 0.20 | 0.94 (0.54-1.63) | .82 |
| Outcome . | NCCH-BMT RIC (vs MAC) . | FHCRC/SCCA-PBSCT CNI + MMF (vs CNI + MTX) . | FHCRC/SCCA-PBSCT Unrelated (vs Related) . | |||
|---|---|---|---|---|---|---|
| HR/OR (95% CI) . | P . | HR/OR (95% CI) . | P . | HR/OR (95% CI) . | P . | |
| Cumulative incidence of NIH chronic GVHD | 0.99 (0.52-1.87) | .97 | 0.90 (0.71-1.14) | 0.38 | 0.83 (0.66-1.05) | .12 |
| Liver involvement with late acute GVHD per the NIH liver score | 1.81 (0.42-7.83) | .43 | 0.35 (0.14-0.88) | 0.026 | 0.79 (0.32-1.93) | .61 |
| Gut involvement with late acute GVHD | 1.76 (0.32-9.73) | .51 | 2.55 (1.00-6.48) | 0.05 | 1.40 (0.57-3.42) | .47 |
| Mouth involvement with NIH chronic GVHD | 0.13 (0.02-0.74) | .022 | 1.09 (0.66-1.81) | 0.73 | 1.19 (0.72-1.96) | .50 |
| Eye involvement with NIH chronic GVHD | 0.71 (0.20-2.58) | .61 | 0.87 (0.54-1.42) | 0.59 | 1.16 (0.71-1.89) | .55 |
| Gut involvement with NIH chronic GVHD | 1.79 (0.10-30.8) | .69 | 1.56 (0.96-2.51) | 0.072 | 1.37 (0.85-2.21) | .19 |
| Liver involvement with NIH chronic GVHD | 0.10 (0.02-0.56) | .009 | 0.61 (0.38-1.00) | 0.044 | 0.71 (0.44-1.13) | .15 |
| Discontinued systemic treatment after late acute GVHD | 1.67 (0.72-3.89) | .23 | 0.88 (0.30-2.57) | 0.81 | 0.94 (0.32-2.78) | .91 |
| NRM after late acute GVHD | NA* | NA* | 2.24 (0.84-6.00) | 0.11 | 1.41 (0.51-3.94) | .51 |
| Progression from late acute GVHD to NIH chronic GVHD | 0.26 (0.03-2.18) | .21 | 0.69 (0.40-1.21) | 0.20 | 0.94 (0.54-1.63) | .82 |
MAC, myeloablative conditioning; RIC, reduced-intensity conditioning.
Not applicable due to no event in the RIC group.